Acute and Cutaneous Porphyria
Porphyria refers to a group of rare inherited metabolic conditions caused by problems in the production of haem, a substance needed to make haemoglobin (the protein in red blood cells that carries oxygen).
Overview
Porphyria refers to a group of rare inherited metabolic conditions caused by problems in the production of haem, a substance needed to make haemoglobin (the protein in red blood cells that carries oxygen). When haem production is disrupted, certain chemicals called porphyrins or porphyrin precursors build up in the body. Porphyrias are broadly divided into acute porphyrias and cutaneous porphyrias. Acute forms mainly affect the nervous system, while cutaneous forms mainly affect the skin.
Causes and Genetics
Porphyrias are caused by changes (mutations) in genes involved in the haem production pathway. Each type of porphyria is linked to deficiency of a specific enzyme in this pathway. Most porphyrias are inherited, commonly in an autosomal dominant pattern, although some are autosomal recessive. In some individuals, symptoms only occur when triggered by certain factors such as medications, alcohol, hormonal changes, dieting, smoking or infections.
Symptoms and Features
Acute Porphyria Symptoms
- Severe abdominal pain
- Nausea and vomiting
- Constipation
- Muscle weakness
- Tingling or numbness
- Anxiety and confusion
- Seizures
- In severe cases, breathing difficulty
Cutaneous Porphyria Symptoms
- Skin fragility
- Blistering on sun-exposed areas (such as the hands and face)
- Slow healing of skin wounds
- Increased hair growth on the face
- Skin darkening or scarring
Acute attacks can develop over hours to days and may require hospital treatment. Urine may appear dark or reddish during an attack. Cutaneous symptoms are often triggered or worsened by sunlight exposure.
Treatment
Patients are usually managed through specialist metabolic or liver centres.
Research and Future Directions
Ongoing research is focused on improving treatments for acute attacks, developing targeted therapies that reduce toxic build-up, and exploring gene-based treatments. Improved awareness, earlier diagnosis and better understanding of triggers continue to reduce complications and improve quality of life for people living with porphyria.